Home About us Contact
|
Home About us Contact | ||
|
|
||
One Cycle (one + cycle)
Selected AbstractsCombined counseling and bupropion therapy for smoking cessation: identification of outcome predictorsDRUG DEVELOPMENT RESEARCH, Issue 3 2006Maria Caterina Grassi Abstract Because some smoking-induced pathologies improve upon discontinuation, strategies have been developed to help smokers quit. The aim of this study was to measure the rate of smokers still abstinent one year after one cycle of a six-week group counseling given alone or in combination with a seven-week period of daily administration of bupropion. We also evaluated the predictor validity of nicotine dependence intensity at enrollment, administering both the Fageström Tolerance Questionnaire (FTQ) and the Severity of Dependence Scale (SDS). Visual Analogue Scale (VAS), to measure the intensity of "smoke craving," was also administered. Two hundred twenty-nine subjects trying to quit smoking were enrolled. Bupropion therapy was accepted by 110 subjects, but only 50 completed the 7-week cycle of therapy. Abstinence rates at one year were 68.0 and 56.6%, respectively, in the group that used bupropion for the scheduled 7 weeks and in the group that discontinued bupropion, and 35.3% in the group with counseling therapy alone. SDS (but not FTQ) scores at enrollment, VAS values for craving at the end of the program, and bupropion therapy were the variables selected by Linear Discriminant Analysis to assign subjects to the Smoker or Non-smoker group, with a global correctness of 70.9%. In conclusion, the efficacy of bupropion largely depends upon its interaction with psychological factors, such as the level of nicotine dependence, craving for nicotine, and the subject's commitment to quit smoking. Drug Dev. Res. 67:271,279, 2006. © 2006 Wiley-Liss, Inc. [source] High-dose chemotherapy for male germ cell tumorINTERNATIONAL JOURNAL OF UROLOGY, Issue 8 2006ISAO HARA Abstract, Today, 20,30% of male patients with advanced germ cell tumor (GCT) do not have durable, complete remission in spite of cis -platinum (CDDP)-based chemotherapy. High-dose chemotherapy (HDCT) has been tried in CDDP refractory GCT patients. Initially HDCT was performed with autologous bone marrow transplantation in heavily treated patients. However, the clinical outcome was not good and the treatment-related death rate was not ignorable. Therefore, earlier introduction of HDCT with peripheral blood stem cell transplantation was preferable as it renders HDCT more effective and less toxic, and multicycle HDCT is feasible. The durable free rate of recent HDCT for refractory GCT patients is 32,65%. HDCT is also performed as first line chemotherapy for poor prognosis GCT patients. Induction chemotherapy followed by multicycles of HDCT was tried. The durable free rate of recent HDCT as first line chemotherapy is 43,73%. Although previous reports suggest the superiority of HDCT, one recent randomized controlled trial (RCT) failed to show an improvement with one cycle of HDCT followed by three cycles of standard-dose chemotherapy (SDCT) compared with four cycles of SDCT. Ongoing RCT comparing multicycles of HDCT with SDCT for poor prognostic GCT patients will clarify the role of HDCT. Recently, new regimens of HDCT containing paclitaxel have been devised. In this review, the history, current status and future of HDCT for advanced or refractory GCT will be discussed. [source] Recombinant human gonadotropins for macaque superovulation: Repeated stimulations and post-treatment pregnanciesJOURNAL OF MEDICAL PRIMATOLOGY, Issue 6 2001C.A. VandeVoort This report summarizes data from the superovulation and ultrasound-guided follicular aspiration of 40 female rhesus monkeys (Macaca mulatta) with recombinant human gonadotropins. Of the animals treated, 12 were stimulated for only one cycle, either because of a poor response to the hormones or due to ectopic ovarian position precluding ease of access via ultrasound. The majority of animals were stimulated for a minimum of 3 cycles and 3 females continued to respond for a minimum of 8 and a maximum of 10 cycles. For those animals with repeated stimulation cycles, the number of follicles developed during each of the stimulation protocols remained relatively comparable. Of the animals mated since cessation of treatment, 70% conceived. There was no difference between the conception rate in this subset of animals and the rest of the macaque breeding colony. These data indicate that participation in these studies does not impact on the reproductive potential of female rhesus monkeys. [source] Visual Tracking and LIDAR Relative Positioning for Automated Launch and Recovery of an Unmanned Rotorcraft from Ships at SeaNAVAL ENGINEERS JOURNAL, Issue 2 2009MATT GARRATT Sensors and systems for a fully autonomous unmanned helicopter have been developed with the aim of completely automating the landing and launch of a small-unmanned helicopter from the deck of a ship. For our scheme, we have combined a laser rangefinder (LRF) system with a visual tracking sensor to construct a low-cost guidance system. Our novel LRF system determines both the distance to and the orientation of the deck in one cycle. We have constructed an optical sensor to complement the laser system, comprising a digital camera interfaced to a Field Programmable Gate Array (FPGA), which enables the entire target tracking computation to be achieved in a very small self-contained form factor. A narrowband light source on the deck is detected by the digital camera and tracked by an algorithm implemented on the FPGA to provide a relative bearing to the deck from the helicopter. By combining the optical sensor bearing with the information from the laser system, an accurate estimate of the helicopter position relative to the deck can be found. [source] Consequences of a decentralized participatory barley breeding programme on changes in SSR allele frequency and diversity in one cycle of selectionPLANT BREEDING, Issue 5 2007F. Fufa Abstract Changes in allele type, allele frequency and genetic diversity because of selection by individual farmers and breeders were assessed using simple sequence repeats (SSRs) during one cycle of selection in a decentralized participatory barley breeding programme. Selection by both breeders and farmers resulted in the loss of a number of alleles in the majority of the locations, with more alleles lost in the heterogeneous breeding materials than in the fixed genotypes, indicating selection against undesirable traits uncovered in the heterogeneous breeding materials that are presumably linked to SSR alleles. After selection, significant allelic frequency changes were observed at several loci in both the germplasm groups. As the selection was conducted independently in each location, an allele had a chance of being selected in more than one location, and therefore considering the whole study area the allelic composition and diversity of the original genetic materials was maintained after the selection. The study showed the importance of decentralized participatory plant breeding in maintaining genetic diversity that helps stabilize and sustain production in unpredictable production conditions. [source] Dramatic Response of Choroidal Metastases from Breast Cancer to a Combination of Trastuzumab and VinorelbineTHE BREAST JOURNAL, Issue 1 2004MRCP, Zee-Wan Wong MBBS Abstract: We report the case of a 57-year-old woman with unilateral choroidal metastases from HER-2-positive breast cancer. She was given trastuzumab and vinorelbine with complete resolution of her visual defect after one cycle of treatment. This article illustrates that treatment using trastuzumab-containing chemotherapy regimens in HER-2-overexpressing breast cancer patients with choroidal metastases may be an alternative therapeutic strategy to initial orbital irradiation., [source] Bortezomib as the Sole Post-Renal Transplantation Desensitization Agent Does Not Decrease Donor-Specific Anti-HLA AntibodiesAMERICAN JOURNAL OF TRANSPLANTATION, Issue 3 2010R. Sberro-Soussan Persistence of donor-specific anti-HLA antibodies (DSA) associated with antibody-mediated graft injuries following kidney transplantation predicts evolution toward chronic humoral rejection and reduced graft survival. Targeting plasma cells, the main antibody-producing cells, with the proteasome inhibitor bortezomib may be a promising desensitization strategy. We evaluated the in vivo efficacy of one cycle of bortezomib (1.3 mg/m2× 4 doses), used as the sole desensitization therapy, in four renal transplant recipients experiencing subacute antibody-mediated rejection with persisting DSA (>2000 [Mean Fluorescence Intensity] MFI). Bortezomib treatment did not significantly decrease DSA MFI within the 150-day posttreatment period in any patient. In addition, antivirus (HBV, VZV and HSV) antibody levels remained stable following treatment suggesting a lack of efficacy on long-lived plasma cells. In conclusion, one cycle of bortezomib alone does not decrease DSA levels in sensitized kidney transplant recipients in the time period studied. These results underscore the need to evaluate this new desensitization agent properly in prospective, randomized and well-controlled studies. [source] CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapyASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Issue 2 2010Nazik HAMMAD Abstract Aims: The aim of this study was to determine the predictive role of pretreatment carbohydrate antigen 19-9 (CA19-9) measurement and its change after one cycle of gemcitabine-based therapy for response, time to progression (TTP) and overall survival (OS). Methods: Analyses were derived from three consecutive gemcitabine-containing phase II clinical trials between 1997 and 2004. Results: A total of 111 patients with pancreas cancer was studied. Baseline CA19-9 concentrations were dichotomized near the median. Lower baseline CA19-9 levels were positively associated with OS (median 9.1 vs 6.1 months, P = 0.0057) and TTP (median 6.4 vs 4.2 months, P = 0.0044). The covariate adjusted hazard ratio (HR) for progression among patients with baseline CA19-9 , 1000 ng/mL was HR = 1.94 (95% CI 1.24,3.02), with P = 0.0035. The covariate adjusted risk of death among patients with baseline CA19-9 , 1000 ng/ml was similarly elevated: HR = 1.90 (95% CI 1.23,2.94), with P = 0.0039. Change in CA19-9 levels from baseline to the end of treatment cycle 1 did not predict objective response (P = 0.75). There was somewhat longer OS (median 8.7 vs 7.1 months) and TTP (median 7.1 vs 5.4 months) in patients with ,50% reduction in serum CA19-9 concentrations, but this was not statistically significant (P = 0.74 and 0.81, respectively). Conclusion: Baseline CA19-9 levels may predict survival in patients with advanced pancreas cancer. The change in CA19-9 levels determined within 1 month of the initiation of therapy did not predict treatment outcome. [source] | ||||||||||